Immunoregulatory Metabolites with Clinical Relevance

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: 15 June 2024 | Viewed by 2658

Special Issue Editors


E-Mail
Guest Editor
Institute of Medical Biochemistry, Medical University of Innsbruck, 6020 Innsbruck, Austria
Interests: immunometabolism; biochemical toxicology; redox biochemistry; aromatic amino acids; neopterin
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I.P. Pavlova 6, 77900 Olomouc, Czech Republic
Interests: neopterin; kynurenine; biomarkers; cancer; immunotherapy

E-Mail Website
Guest Editor
Institute of Biological Chemistry, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria
Interests: neopterin; tryptophan; kynurenine; analytical chemistry; biomarkers; immunobiochemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Numerous metabolites significantly contribute to the regulation of immune responses. Their modes of action can vary widely, ranging from immune activation to the termination of inflammation, the suppression of responses, and the mediation of tolerance.  A key example is cytokine interferon-gamma, which affects a variety of metabolic pathways. In this context, immune-mediated tryptophan catabolism along the kynurenine axis is probably one of the most reviewed metabolic pathways, with clinical relevance in chronic immunopathologies. However, several other metabolite classes are co-regulated with cytokine responses, linking, e.g., altered nutrient and energy metabolism to immunological processes relevant to disease.  In this Special Issue, metabolites that influence immunological regulatory circuits and have clinical relevance, e.g., as potential drug targets, or with predictive or prognostic significance, are presented. These may include but are not limited to amino acids and derivatives, biogenic amines, lipid classes, pteridines, and signaling gases. Clinical and translational studies as well as basic experimental research will be covered.

Prof. Dr. Johanna M. Gostner
Prof. Dr. Bohuslav Melichar
Prof. Dr. Dietmar Fuchs
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunometabolism
  • (metabolite) biomarker
  • immunoregulation
  • crosstalk of immunity and metabolism
  • clinical relevance
  • immunobiochemistry

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1904 KiB  
Article
Positive Effects of Probiotic Therapy in Patients with Post-Infectious Fatigue
by Katharina Obermoser, Natascha Brigo, Andrea Schroll, Pablo Monfort-Lanzas, Johanna M. Gostner, Sabine Engl, Simon Geisler, Miriam Knoll, Harald Schennach, Günter Weiss, Dietmar Fuchs, Rosa Bellmann-Weiler and Katharina Kurz
Metabolites 2023, 13(5), 639; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo13050639 - 08 May 2023
Cited by 1 | Viewed by 2239
Abstract
Post-infectious fatigue is a common complication that can lead to decreased physical efficiency, depression, and impaired quality of life. Dysbiosis of the gut microbiota has been proposed as a contributing factor, as the gut–brain axis plays an important role in regulating physical and [...] Read more.
Post-infectious fatigue is a common complication that can lead to decreased physical efficiency, depression, and impaired quality of life. Dysbiosis of the gut microbiota has been proposed as a contributing factor, as the gut–brain axis plays an important role in regulating physical and mental health. This pilot study aimed to investigate the severity of fatigue and depression, as well as the quality of life of 70 patients with post-infectious fatigue who received a multi-strain probiotic preparation or placebo in a double-blind, placebo-controlled trial. Patients completed questionnaires to assess their fatigue (fatigue severity scale (FSS)), mood (Beck Depression Inventory II (BDI-II)), and quality of life (short form-36 (SF-36)) at baseline and after 3 and 6 months of treatment. Routine laboratory parameters were also assessed, including immune-mediated changes in tryptophan and phenylalanine metabolism. The intervention was effective in improving fatigue, mood, and quality of life in both the probiotic and placebo groups, with greater improvements seen in the probiotic group. FSS and BDI-II scores declined significantly under treatment with both probiotics and placebo, but patients who received probiotics had significantly lower FSS (p < 0.001) and BDI-II (p < 0.001) scores after 6 months. Quality of life scores improved significantly in patients who received probiotics (p < 0.001), while patients taking a placebo only saw improvements in the “Physical limitation” and “Energy/Fatigue” subcategories. After 6 months neopterin was higher in patients receiving placebo, while no longitudinal changes in interferon-gamma mediated biochemical pathways were observed. These findings suggest that probiotics may be a promising intervention for improving the health of patients with post-infectious fatigue, potentially through modulating the gut–brain axis. Full article
(This article belongs to the Special Issue Immunoregulatory Metabolites with Clinical Relevance)
Show Figures

Figure 1

Back to TopTop